Hayley Virgil

Investigators report favorable overall survival among patients with chronic lymphocytic leukemia who receive ibrutinib/venetoclax over FCR.

Investigators indicate that ongoing efforts should focus on meeting the needs of adult cancer survivors with co-morbid substance use disorder, with an emphasis on prioritizing populations in which the disorder is highly present.

Conversely, investigators noted that there was an overall survival benefit when dose-dense MVAC was used in the neoadjuvant setting.

Cancer incidence appears to have increased from 2015 to 2019 across several disease types, including breast, pancreatic, and uterine cancers.

Patients with metastatic cancer who are receiving treatment at nonacademic or low-volume facilities appear more likely to receive end of life immunotherapy.

A promising new treatment combination of frontline olaparib plus abiraterone/prednisone has emerged for advanced prostate cancer with specific genetic alterations.

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.

Frontline olaparib plus abiraterone/prednisone improved progression-free survival and responses in patients with metastatic castration-resistant prostate cancer compared with each of the components of the therapy alone.

Patients with benign thyroid tumors resected with a transoral endoscopic thyroidectomy vestibular approach have less complications vs those treated with a standard surgical approach.